argenx US is a global immunology company dedicated to transforming the treatment landscape for patients suffering from severe autoimmune diseases. With a commitment to innovation and a rich pipeline of first-in-class therapies, including VYVGART®, argenx aims to reach 50,000 patients by 2030. The company maintains its roots as a science-based start-up while expanding its operations to deliver meaningful solutions for patients. argenx fosters an inclusive environment that values diversity and offers endless opportunities for growth, empowering its employees to make a significant impact in the field of immunology.